Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Zai LabAscendis Pharma A/SArrowhead PharmaceuticalsACADIA PharmaceuticalsJazz Pharmaceuticals
SymbolNASDAQ:ZLABNASDAQ:ASNDNASDAQ:ARWRNASDAQ:ACADNASDAQ:JAZZ
Price Information
Current Price$164.48$131.85$70.99$20.87$167.52
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.41.51.31.92.1
Analysis Score2.53.52.44.23.4
Community Score2.32.62.53.23.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.81.71.71.7
Earnings & Valuation Score0.60.60.00.61.9
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$197.85$192.22$85.31$32.76$187.37
% Upside from Price Target20.29% upside45.79% upside20.17% upside56.99% upside11.85% upside
Trade Information
Market Cap$14.57 billion$7.09 billion$7.37 billion$3.34 billion$9.44 billion
Beta0.950.771.621.441.08
Average Volume471,913208,665795,6252,192,327710,664
Sales & Book Value
Annual Revenue$12.98 million$14.98 million$87.99 million$339.08 million$2.16 billion
Price / Sales1,122.62473.0983.749.854.36
CashflowN/AN/AN/AN/A$22.82 per share
Price / CashN/AN/AN/AN/A7.34
Book Value$5.07 per share$15.87 per share$4.51 per share$4.54 per share$54.99 per share
Price / Book32.448.3115.744.603.05
Profitability
Net Income$-195,070,000.00$-244,180,000.00$-84,550,000.00$-235,260,000.00$523.37 million
EPS($3.03)($5.25)($0.84)($1.60)$14.60
Trailing P/E RatioN/AN/AN/AN/A52.85
Forward P/E RatioN/AN/AN/AN/A10.96
P/E GrowthN/AN/AN/AN/A4.64
Net MarginsN/A-4,042.79%-96.09%-63.92%7.86%
Return on Equity (ROE)N/A-55.72%-17.37%-40.35%20.16%
Return on Assets (ROA)N/A-49.42%-15.19%-34.72%10.85%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.55%
Current Ratio8.57%14.80%7.92%7.95%3.98%
Quick Ratio8.46%14.80%7.92%7.86%3.84%
Ownership Information
Institutional Ownership Percentage81.32%N/A65.52%93.54%95.67%
Insider Ownership PercentageN/A40.00%4.00%27.70%4.60%
Miscellaneous
Employees1,1944822326011,940
Shares Outstanding88.59 million53.75 million103.79 million160.05 million56.33 million
Next Earnings DateN/A5/18/2021 (Estimated)5/4/2021 (Confirmed)5/5/2021 (Confirmed)5/4/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
BRIEF-Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes OfferingBRIEF-Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering
msn.com - April 22 at 7:36 PM
Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes OfferingJazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering
finance.yahoo.com - April 22 at 7:36 PM
Sulglicotide API Market Size 2021-Top Companies, Growth Rate, Trends, Product Profiles, Development Plans and Demand Status Forecast to 2025Sulglicotide API Market Size 2021-Top Companies, Growth Rate, Trends, Product Profiles, Development Plans and Demand Status Forecast to 2025
marketwatch.com - April 22 at 9:36 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $198.00 at Cantor FitzgeraldJazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $198.00 at Cantor Fitzgerald
americanbankingnews.com - April 21 at 9:42 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $198.00 at Cantor FitzgeraldJazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $198.00 at Cantor Fitzgerald
marketbeat.com - April 21 at 7:48 AM
Novel Approach to Cancer From Lixte Biotechnology Could Be a General way to Enhance a Variety of Standard TreatmentsNovel Approach to Cancer From Lixte Biotechnology Could Be a General way to Enhance a Variety of Standard Treatments
markets.businessinsider.com - April 20 at 2:19 PM
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Increased to $202.00 by Analysts at Stifel NicolausJazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Increased to $202.00 by Analysts at Stifel Nicolaus
americanbankingnews.com - April 20 at 10:46 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $202.00 at Stifel NicolausJazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $202.00 at Stifel Nicolaus
americanbankingnews.com - April 20 at 10:08 AM
Stifel Nicolaus Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00Stifel Nicolaus Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00
americanbankingnews.com - April 20 at 10:08 AM
BRIEF-Jazz Pharmaceuticals Presents Phase 3 Study Results Of Xywav Oral Solution In Adults With Idiopathic Hypersomnia At 2021 American Academy Of Neurology Annual MeetingBRIEF-Jazz Pharmaceuticals Presents Phase 3 Study Results Of Xywav Oral Solution In Adults With Idiopathic Hypersomnia At 2021 American Academy Of Neurology Annual Meeting
msn.com - April 20 at 9:18 AM
Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual MeetingJazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 20 at 9:18 AM
Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured NotesJazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes
finance.yahoo.com - April 20 at 9:18 AM
Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021
finance.yahoo.com - April 19 at 5:27 PM
Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Rock Solid Balance SheetJazz Pharmaceuticals (NASDAQ:JAZZ) Has A Rock Solid Balance Sheet
ca.finance.yahoo.com - April 17 at 1:11 AM
Stifel Nicolaus Stick to Their Buy Rating for Jazz PharmaceuticalsStifel Nicolaus Stick to Their Buy Rating for Jazz Pharmaceuticals
investing.com - April 15 at 6:08 PM
Stifel Nicolaus Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00Stifel Nicolaus Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $202.00
americanbankingnews.com - April 14 at 8:54 AM
US FDA accepts and grants priority review status to Jazz’s sNDA for Xywav to treat idiopathic hypersomniaUS FDA accepts and grants priority review status to Jazz’s sNDA for Xywav to treat idiopathic hypersomnia
pharmabiz.com - April 14 at 5:17 AM
Jazz Pharmaceuticals Announces FDA Acceptance and…Jazz Pharmaceuticals Announces FDA Acceptance and…
pharmiweb.com - April 13 at 8:36 AM
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic HypersomniaJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia
finance.yahoo.com - April 12 at 9:11 AM
Fitch Assigns First-Time Rating of BB- to Jazz Pharmaceuticals plcFitch Assigns First-Time Rating of 'BB-' to Jazz Pharmaceuticals plc
fitchratings.com - April 9 at 10:13 PM
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $247,440.00 in StockJazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $247,440.00 in Stock
americanbankingnews.com - April 6 at 7:36 PM
Jazz Pharmaceuticals (NASDAQ:JAZZ) versus OptiNose (NASDAQ:OPTN) Head to Head ContrastJazz Pharmaceuticals (NASDAQ:JAZZ) versus OptiNose (NASDAQ:OPTN) Head to Head Contrast
americanbankingnews.com - April 6 at 10:22 AM
Oyster Point Pharma Announces New Appointment to Board of DirectorsOyster Point Pharma Announces New Appointment to Board of Directors
finance.yahoo.com - April 5 at 6:22 AM
Zacks: Brokerages Anticipate Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to Announce $3.69 Earnings Per ShareZacks: Brokerages Anticipate Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to Announce $3.69 Earnings Per Share
americanbankingnews.com - April 4 at 10:16 PM
US FDA approves revised label for Jazz Pharma’s Vyxeos to include new indication to treat secondary acute myeloid leukemia in pediatric patientsUS FDA approves revised label for Jazz Pharma’s Vyxeos to include new indication to treat secondary acute myeloid leukemia in pediatric patients
pharmabiz.com - April 1 at 9:51 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $176.00Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $176.00
marketbeat.com - April 1 at 8:51 AM
Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $176.00Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $176.00
americanbankingnews.com - April 1 at 8:16 AM
DateCompanyBrokerageAction
4/20/2021Zai LabSVB LeerinkBoost Price Target
4/13/2021Zai LabThe Goldman Sachs GroupBoost Price Target
4/13/2021Zai LabGuggenheimBoost Price Target
2/8/2021Zai LabJefferies Financial GroupBoost Price Target
11/16/2020Zai LabJPMorgan Chase & Co.Boost Price Target
12/30/2019Zai LabCitigroupBoost Price Target
9/4/2019Zai LabChina Renaissance SecuritiesInitiated Coverage
7/12/2019Zai LabBank of AmericaInitiated Coverage
7/5/2019Zai LabMacquarieInitiated Coverage
1/29/2019Zai LabCredit Suisse GroupInitiated Coverage
3/30/2021Ascendis Pharma A/SOppenheimerDowngrade
3/18/2021Ascendis Pharma A/SCanaccord GenuityBoost Price Target
3/11/2021Ascendis Pharma A/SStifel NicolausInitiated Coverage
12/17/2020Ascendis Pharma A/SBerenberg BankInitiated Coverage
11/13/2020Ascendis Pharma A/SMorgan StanleyBoost Price Target
11/12/2020Ascendis Pharma A/SWells Fargo & CompanyBoost Price Target
9/30/2020Ascendis Pharma A/SWedbushBoost Price Target
5/20/2020Ascendis Pharma A/SCSFBBoost Price Target
2/8/2021Arrowhead PharmaceuticalsB. RileyBoost Price Target
2/5/2021Arrowhead PharmaceuticalsPiper SandlerBoost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan CapitalBoost Price Target
2/5/2021Arrowhead PharmaceuticalsHC WainwrightBoost Price Target
12/21/2020Arrowhead PharmaceuticalsRobert W. BairdDowngrade
12/15/2020Arrowhead PharmaceuticalsUBS GroupInitiated Coverage
11/24/2020Arrowhead PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/24/2020Arrowhead PharmaceuticalsCantor FitzgeraldBoost Price Target
11/19/2020Arrowhead PharmaceuticalsSmith Barney CitigroupInitiated Coverage
11/19/2020Arrowhead PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
4/13/2021ACADIA PharmaceuticalsMizuhoReiterated Rating
4/5/2021ACADIA PharmaceuticalsRaymond JamesDowngrade
4/5/2021ACADIA PharmaceuticalsNeedham & Company LLCLower Price Target
2/24/2021Jazz PharmaceuticalsCowenBoost Price Target
11/3/2020Jazz PharmaceuticalsBarclaysBoost Price Target
10/20/2020Jazz PharmaceuticalsTruistBoost Price Target
(Data available from 4/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.